Fareston
toremifene · Orion Corporation
AUTHORISED IN THE EUWhat Fareston is used for
First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.Fareston is not recommended for patients with estrogen receptor negative tumours.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Fareston
- Active substance
- toremifene
- Disease area
- Breast Neoplasms
- Medicine group
- Endocrine therapy
- ATC code
- L02BA02
- Marketing authorisation holder
- Orion Corporation
- Authorised in the EU since
- 1996
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Fareston used for?
First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.Fareston is not recommended for patients with estrogen receptor negative tumours.
What is the active substance in Fareston?
Fareston contains toremifene.
Who makes Fareston?
The EU marketing authorisation holder is Orion Corporation.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU